The Efficacy and Safety of 4-n-butylresorcinol 0.1% Cream for the Treatment of Melasma: A Randomized Controlled Split-face Trial.
- Author:
Sun Young HUH
1
;
Jung Won SHIN
;
Jung Im NA
;
Chang Hun HUH
;
Sang Woong YOUN
;
Kyoung Chan PARK
Author Information
- Publication Type:Comparative Study ; Randomized Controlled Trial ; Original Article
- Keywords: 4-n-butylresorcinol; Melasma; Randomized controlled trial; Split-face design; Treatment
- MeSH: Female; Humans; Hyperpigmentation; Melanins; Melanosis; Monophenol Monooxygenase; Oxidoreductases; Photography; Resorcinols
- From:Annals of Dermatology 2010;22(1):21-25
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Melasma is a common acquired symmetrical hypermelanosis that occurs on sun-exposed areas, and it is frequently observed among women. Various treatment modalities have been tried, but none are completely satisfactory. 4-n-butylresorcinol, which is a resorcinol derivative that has an inhibitory effect on both tyrosinase and tyrosinase-related protein-1, was introduced in 1995 and it has received increasing attention as a new hypopigmenting agent. However, the hypopigmenting effect of 4-n-butylresorcinol in human subjects has only been shown in a few studies. OBJECTIVE: The aim of this study was to investigate the hypopigmenting efficacy and safety of 4-n-butylresorcinol 0.1% cream for the treatment of melasma. METHODS: Twenty patients with melasma were enrolled to this randomized, double-blind, vehicle-controlled, split-face comparative study. The patients were instructed to apply 4-n-butylresorcinol 0.1% cream or vehicle to each side of the face twice daily for 8 weeks. Mexameter measurements were performed along with photography at baseline, 4 weeks and 8 weeks. Adverse events were observed and recorded throughout the study. RESULTS: All the patients completed the study. Mexameter measurements demonstrated that the melanin index of the treated side showed a significant decrease when compared with that of the vehicle-treated side after 4 weeks (p=0.006) and after 8 weeks (p<0.0005). All the adverse reactions were mild and transient. CONCLUSION: 4-n-butylresorcinol 0.1% cream showed rapid efficacy and it was well tolerated when used for the treatment of melasma.
